

## Rena Kaminsky

### Special Counsel

---



rkaminsky@cooley.com

Life Sciences

Life Sciences Corporate Partnering and Licensing

+1 650 843 5160

Palo Alto

---

Rena Kaminsky represents biotechnology, medical device, and other public and private life sciences companies in a wide range of intellectual property and commercial transactions, including corporate partnering, licenses, research and development collaborations, and manufacturing and supply arrangements.

Rena's recent transactions include:

- Neurocrine Biosciences in its gene therapy collaboration with Voyager Therapeutics valued at \$165 million upfront and up to \$1.7 billion in milestone payments
- iNtRON Biotechnology in its license agreement with Roivant Sciences for endolysin biologics for treating infectious diseases
- Fate Therapeutics in its strategic collaboration with ONO Pharmaceutical for CAR-T cell cancer immunotherapies
- Arena Pharmaceuticals in its license agreement with Everest Medicines for China, Taiwan and South Korea valued at up to \$212 million
- Calithera Biosciences in two clinical trial collaborations with Pfizer
- HanAll BioPharma in its \$500 million license agreement with Roivant Sciences
- HanAll BioPharma in its collaboration and license agreement with Harbour BioMed for \$81 million upfront and potential milestones
- Molecular Partners AG in its collaboration and option agreement with Allergan for multi-target discovery programs valued up to \$1.4 billion
- Sangamo Therapeutics in its collaboration with Kite/Gilead to develop next-generation engineered cell therapies for the treatment of cancer for \$150 million upfront, up to \$3 billion in milestones and tiered royalties.
- Sangamo Therapeutics in its collaboration and license agreement with Pfizer to develop and commercialize gene therapy programs for hemophilia A for \$70 million upfront, potential milestones up to \$475 million and tiered double digit royalties.
- Calithera Biosciences in its collaboration with Incyte for the development and commercialization of CB-1158, a small molecule arginase inhibitor, including an upfront payment to Calithera of \$45 million, equity investment of \$8 million, milestones, profit-share in the US, and milestones and other royalties ex-US
- Takeda in its collaboration agreement with NuBiyota to develop and commercialize microbiome

therapeutics for GI indications

## Education

Stanford Law School

JD, 2006

Yale University

BS, 1992

## Admissions & Credentials

California

Registered to practice before the United States Patent and Trademark Office (USPTO)

## Memberships & Affiliations

American Bar Association (ABA)